Dermatomyositis and Polymyositis

There is a great unmet need for new treatments in the inflammatory myopathies.  We have participated in a phase 1b study of the anti-CD20 small modular immunopharmaceutical TRU-15 for polymyositis and dermatomyositis.   In addition, Dr. Eggebeen, who has advanced training in myositis care at the University of Pittsburg, had done translational research linking myositis associated antibodies to the development of intersitial lung disease.  Subsequently Dr. Eggebeen was a principle investigator in the National Institute of Health funded, first of it kind trial the "Rituximab in Myositis Study".  

Enrollment is now closed for this study, but if you are interested you can learn more at 

© 2019 West Michigan Rheumatology, PLLC  1155 East Paris SE, Suite 100  Grand Rapids, MI 49546   Voice 616.459.8088    FAX 616.459.8312